

No Compromise! Improved Sensitivity for Negatively-Ionizing Substances

Rob Lee¹, Scott Freeto², Mike Wakefield³, and Michelle Wood¹

¹Waters Corporation, Wilmslow, UK; ²Waters Corporation, Beverley, MA, USA; ³Waters Corporation, Pleasanton, CA, USA

GOAL

To assess the impact of alternate mobile phases on the sensitivity for a series of negatively-ionizing substances.

BACKGROUND

In 2014, Waters released the first version of the Forensic Toxicology Screening Application Solution with UNIFI[®],¹ which comprised acquisition of MS^E data using a time-of-flight mass spectrometer operated in electrospray positive ionization mode (ESI+). Data were subsequently compared with a comprehensive library containing more than 1,000 toxicologically-relevant substances.^{2,3}

Since this time, on-going efforts have been underway to further improve the forensic solution by continuing to expand the library content, to include novel psychoactive substances and their metabolites, but also to include substances that may preferentially ionize in negative mode (ESI-), such as the barbiturates, cannabinoids, diuretics, and the non-steroidal anti-inflammatory drugs (NSAIDs).^{4,5} For convenience, some screening approaches employ the same chromatographic conditions for both positive and negative ionization modes however, the impact of this approach should be evaluated, particularly with regards to the effect on sensitivity.

Altered mobile phases provide improved sensitivity when using the Waters Forensic Toxicology Screening Application Solution with UNIFI in negative ionization mode.




Figure 1. Improvement in both 3D peak response and signal-to-noise ratio for 2500 ng/mL injection of THC standard when using the altered mobile phases (upper chromatogram) in comparison with the original mobile phases (lower chromatogram).

Consequently, the aim of this study was to compare the sensitivity obtained for a series of negatively-ionizing substances when analyzed using the mobile phases that are usually employed in ES+ mode (Method 1), with some alternative chromatographic conditions, that are based on a previously-reported method for barbiturates (Method 2).⁶

EXPERIMENTAL

Sample preparation

Individual standards were prepared at 1 mg/mL in methanol, then diluted in 10% acetonitrile in water for injection. The final concentrations ranged from 20 ng/mL to 2,500 ng/mL.

LC conditions

LC system:	ACQUITY UPLC® I-Class (FTN)
Column:	ACQUITY UPLC HSS C ₁₈ , 2.1 x 150 mm, 1.8 µm
Vials:	Waters Maximum Recovery Vials
Column temp.:	50 °C
Sample temp.:	10 °C
Injection vol.:	10 µL
Flow rate:	0.4 mL/min
Mobile phase A method 1:	5 mM ammonium formate pH 3.0
Mobile phase A method 2:	Water containing 0.001% formic acid
Mobile phase B method 1:	Acetonitrile containing 0.1% formic acid
Mobile phase B method 2:	Acetonitrile containing 0.001% formic acid
Gradient:	Isocratic at 87% A for 0.5 min then to 5% A at 4.5 min, hold for 1 min before switching to 87% A
Run time:	7.5 min

MS^E conditions

MS system:	Xevo G2-S QTof
Ionization mode:	ESI-
Source temp.:	150 °C
Desolvation temp.:	400 °C
Desolvation gas:	800 L/h
Reference mass:	Leucine enkephalin [M-H] ⁻ <i>m/z</i> = 554.2620
Acquisition range:	<i>m/z</i> 50-1000
Scan time:	0.1 s
Capillary voltage:	1.5 KV
Cone voltage:	20 V
Collision energy:	Function 1: 6 eV Function 2: Ramped 10 to 40 eV

RESULTS

Sixty-two compounds, including barbiturates, cannabinoids, diuretics, NSAIDs, and steroids, were analyzed in triplicate. The retention times for a selection of the compounds, under both sets of mobile phases evaluated, are listed in Table 1, together with the observed increase in 3-dimensional (3D) peak response and signal-to-noise ratio, with the alternative mobile phases.

Sixty of the sixty-two compounds evaluated showed an increase in 3D peak response when using the alternate mobile phases, with 75% of the compounds tested showing a greater than two-fold increase, and only two compounds showing a reduced 3D peak response. The greatest increase in 3D response was for THC, which is illustrated in Figure 1, and showed an increase of more than 50-fold alongside a dramatic increase in signal-to-noise ratio.

A small number of compounds were only identified, at the concentrations investigated, when using the altered mobile phases. The signal-to-noise ratio comparison between the two methods, for a selection of compounds, is highlighted in Table 1, and complements the increase in 3D response. Only small differences in retention time were observed when switching between the two mobile phases.

Analyte	Drug class	Injection conc. ng/mL	Degree of improvement (method 2/1)		Retention time (min)	
			3D peak response	Signal-to-noise ratio	Method 1	Method 2
Phenobarbital	barbiturate	100	15	17	2.9	2.9
Secobarbital	barbiturate	100	11	11	3.5	3.5
Carboxy-THC	cannabinoid	20	3	3	5.0	5.0
THC	cannabinoid	2500	67	445	5.7	5.8
Amiloride	diuretic	250	3	3	1.1	1.0
Furosemide	diuretic	250	7	3	3.1	3.1
Naproxen	NSAID	400	23	20	3.8	3.8
Ibuprofen	NSAID	1000	52	73	4.4	4.5
Hydrocortisone	steroid	400	6	5	3.0	3.0
Triamcinolone	steroid	400	5	3	2.6	2.6

Table 1. Improvement in 3D peak response and sensitivity for a selection of analytes, using the two sets of mobile phases along with their retention times.

SUMMARY

While it is certainly possible to use the same mobile phases for screening analysis in both positive and negative mode, this simple study clearly demonstrates that these compromises in chromatographic conditions can influence analytical performance and sensitivity, and in some cases, this can be significant. In a toxicological screening this can yield false negative results, particularly for the cannabinoids which are the most-commonly encountered illicit drug substances. For this reason the expanded Waters Forensic Toxicology Screening Application Solution with UNIFI includes a fully-optimized chromatographic method for more efficient, more accurate toxicological screening of negatively-ionizing substances.

References

1. Forensic Toxicology Screening Application Solution with UNIFI. Waters Brochure ([P/N 720004830EN](#)).
2. Wood M. The Utility of MS^E for Toxicological Screening. Waters Tech Brief 2014 ([P/N 720005198EN](#)).
3. Roberts M and Wood M. Analysis of Beta-Blockers using UPLC with Accurate Mass Screening. Waters Application Note 2014 ([P/N 720005188EN](#)).
4. Lee R and Wood M. Using the Waters Forensic Toxicology Screening Application Solution with UNIFI to determine diuretics in urine. Waters Application Note 2015 ([P/N 720005391EN](#)).
5. Lee R and Wood M. Screening for Cannabinoids using the Waters Forensic Toxicology Application Solution with UNIFI. Waters Application Note 2015 ([P/N 720005413EN](#)).
6. Lee R, et al. Quantitative Analysis of Barbiturates in Urine Using UPLC/MS/MS. Waters Application Note 2014 ([P/N 720004466EN](#)).

Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, UNIFI, and ACQUITY UPLC are registered trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com